Herantis Pharma applies for delisting regarding the secondary listing of its shares from Nasdaq First North Growth Market Sweden
Herantis Pharma Plc, Company release, 1 December 2022 at 11:30 EET
Herantis Pharma will be traded solely on Nasdaq First North Growth Market Finland under the trading code: HRTIS (ISIN code: FI4000087861)
Herantis Pharma Plc ("Herantis") developing disease modifying therapies for Parkinson’s disease, has applied for delisting of its shares from Nasdaq First North Growth Market Sweden (“Nasdaq FN GM Sweden”).
When adopting the decision on applying for the delisting, the Board of Directors considered the development of trading since the company listed its shares on Nasdaq FN GM Sweden in 2019, noting the low level of trading volumes as well as the small number of current shareholders holding their shares through Euroclear Sweden AB. The Company has also considered the additional costs related to maintaining this secondary listing for a company of its size as well as the administrative burden of complying with the listing rules of another market in addition to its home market in Finland.
The Company wants to remind Herantis’ shareholders holding their shares through Euroclear Sweden AB that even while the listing of Herantis' shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in Herantis' shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy. In order to effectuate such cross-border settlement, the shareholders should contact their respective custodian or Herantis Issuing Agent Aqurat Fondkommission AB ([email protected]) for more information.
The last day of trading on Nasdaq FN GM Sweden is expected to be January 31, 2023. More information about the delisting will be provided once Nasdaq Sweden has decided on the application.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: [email protected]
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400
Company website: www.herantis.com
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative biotech company developing disease modifying therapies for Parkinson’s disease. Herantis lead product HER-096, is an advanced small and synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration.
The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.herantis.com.
Rolf Classon föreslås till ny ordförande i BICO Group AB (publ
Valberedningen i BICO Group AB meddelar idag att den föreslår årsstämman att välja Rolf Classon till ny styrelseordförande i bolaget. Rolf Classon är sedan april 2022 styrelseledamot i BICO Group AB. Rolf Classon är en erfaren ledare inom hälso- och sjukvårdsbranschen med många års erfarenhet i leda...
Rolf Classon proposed as new Chairman of BICO Group AB (publ)
The Nomination Committee of BICO Group AB today announces the proposal of Rolf Classon to the Annual General Meeting as the company’s new Chairman of the Board. Rolf Classon has been a board member of BICO Group AB since April 2022. Rolf Classon is a seasoned leader in the healthcare industry, havin...
Hemcheck has received a follow up order from its French distributor
Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood g...
Hemcheck har fått uppföljningsorder från sin franska distributör
Hemcheck Sweden AB producerar och marknadsför ett patenterat CE-märkt koncept för patientnära detektion av hemolys. Hemolys, dvs. trasiga röda blodkroppar, är den vanligaste orsaken till att blodprov inte kan analyseras med korrekta resultat. Det är även en biomarkör för akuta patienttillstånd. Konc...